These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 33222040)
1. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials. Guo C; Yan C; Qu L; Du R; Lin J Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040 [TBL] [Abstract][Full Text] [Related]
2. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961 [TBL] [Abstract][Full Text] [Related]
3. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. Wang H; Xu T; Zheng L; Li G Int J Gynecol Cancer; 2018 Jun; 28(5):903-914. PubMed ID: 29561301 [TBL] [Abstract][Full Text] [Related]
4. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. Wu YS; Shui L; Shen D; Chen X Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044 [TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials. Li X; Zhu S; Hong C; Cai H Curr Med Res Opin; 2016; 32(3):555-62. PubMed ID: 26652645 [TBL] [Abstract][Full Text] [Related]
6. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials. Jiang Y; Sun X; Kong B; Jiang J Medicine (Baltimore); 2018 Aug; 97(34):e11920. PubMed ID: 30142803 [TBL] [Abstract][Full Text] [Related]
7. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis. Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396 [TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Sun L; Ma JT; Zhang SL; Zou HW; Han CB Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis. Zhang C; Zhao W J Ovarian Res; 2022 Aug; 15(1):99. PubMed ID: 35996165 [TBL] [Abstract][Full Text] [Related]
12. Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment. Ding SS; Li L; Yu CX J BUON; 2014; 19(4):965-72. PubMed ID: 25536603 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials. Marchetti C; De Felice F; Palaia I; Musella A; Di Donato V; Gasparri ML; Musio D; Muzii L; Tombolini V; Panici PB Oncotarget; 2016 Mar; 7(11):13221-7. PubMed ID: 26657509 [TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials. Huang D; Ke L; Cui H; Li S; Sun F BMC Womens Health; 2024 Jan; 24(1):34. PubMed ID: 38218775 [TBL] [Abstract][Full Text] [Related]
16. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base. Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. Ye Q; Chen HL Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268 [TBL] [Abstract][Full Text] [Related]
18. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials. Li J; Zhou L; Chen X; Ba Y Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028 [TBL] [Abstract][Full Text] [Related]
20. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. Zhou M; Yu P; Qu X; Liu Y; Zhang J PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]